Manufactured by Eli Lilly, the medication has successfully passed phase I and II clinical trials and is currently in phase III trials
Metabolites 6 , 24 (2016)
Teratogenic Effects: Chorionic gonadotropin may cause fetal harm when administered to a pregnant woman
Medicare Part D statutorily excludes weight-loss drugs from coverage, whereas only a minority of state Medicaid programs cover obesity medications
[DOI] [PubMed] [Google Scholar] 291.Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, Fuhlbrigge RC, Kupper TS, Sayegh MH, Frank MH
Do not start, adjust, or discontinue any GLP-1 therapy without consulting your healthcare provider